Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Long-term ICD survival more evident in patients with ischaemic HF, NYHA functional class II

01 Aug 2020
The implantable cardioverter defibrillator (ICD) is a small device implanted under the skin in the chest, to help control life-threatening arrhythmias.

Heterogenous treatment-related patterns of long-term survival with implantable cardioverter defibrillator (ICD) therapy have been observed among patients who participated in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) over 11 years of follow-up, with the benefit most apparent for those with ischaemic heart failure (HF) and those with New York Heart Association (NYHA) functional class II symptoms at trial enrolment.

Between 2010 and 2011, the authors analysed mortality outcomes for the 1,855 patients alive at the end of SCD-HeFT and combined these data with the 666 deaths from the original study to compare long-term outcomes overall and for key prespecified subgroups.

Over a median (25th to 75th percentiles) follow-up of 11.0 years, overall survival benefit favoured the ICD group compared with the placebo group (hazard ratio [HR], 0.87, 95 percent confidence interval [CI], 0.76–0.98; p=0.028) in intention-to-treat analysis. The ICD benefit attenuated after 6 years (pinteraction=0.0015) when treatment benefit was analysed as a function of time from randomization.

In subgroup analysis, ICD benefit in the long term varied depending on the HF aetiology and NYHA functional class: ischaemic HF (HR, 0.81, 95 percent CI, 0.69–0.95; p=0.009); nonischaemic HF (HR, 0.97, 95 percent CI, 0.79–1.20; p=0.802); NYHA functional class II (HR, 0.76, 95 percent CI, 0.65–0.90; p=0.001); NYHA functional class III (HR, 1.06, 95 percent CI, 0.86–1.31; p=0.575).

The SCD-HeFT randomly assigned 2,521 patients with moderate HF to amiodarone, placebo drug, or ICD therapy, with follow-up ending on 31 October 2003. Over a median follow-up of 45.5 months, amiodarone showed no effect on survival as compared with placebo, but ICD led to a 23-percent reduction in all-cause mortality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.